Palivizumab
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Palivizumab: From RSV Prophylaxis to Benign Neoplasm of Tongue
One-Sentence Summary
Palivizumab is a monoclonal antibody against the RSV F glycoprotein, used to prevent respiratory syncytial virus (RSV) infection in high-risk infants by neutralizing the virus and blocking cell entry. The TxGNN model predicts it may be effective for Benign Neoplasm of Tongue, but this prediction is currently supported by 0 clinical trials and 0 publications, and the evidence pack itself flags it as a likely false positive.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | RSV (呼吸道融合病毒) 感染預防 |
| Predicted New Indication | Benign neoplasm of tongue |
| TxGNN Prediction Score | 99.94% |
| Evidence Level | L5 |
| New Zealand Market Status | 未上市 (Not marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed formal mechanism-of-action (MOA) data is marked as a data gap in this evidence pack. However, the model's own rationale text describes palivizumab's known mechanism: it is a monoclonal antibody that binds the RSV fusion (F) glycoprotein and neutralizes the virus, blocking its entry into respiratory epithelial cells. This is a purely antiviral mechanism with no known antineoplastic, antiproliferative, or tissue-remodeling activity.
There is no plausible biological link between RSV neutralization and the pathophysiology of a benign tongue neoplasm (localized epithelial/connective tissue proliferation). The evidence pack explicitly flags this concern: all 10 top-ranked predicted indications for this drug cluster tightly around a score of ~0.9994 (ranks 871–917) and are almost entirely unrelated tumor/cyst entities across disparate anatomic sites and cell lineages (tongue, epiglottis, testis, jugular foramen schwannoma, thyroglossal duct cyst, etc.). This tight score clustering across mechanistically unrelated diseases is a strong signature of a knowledge-graph embedding artifact rather than a genuine pharmacological signal.
Given the absence of any supporting clinical trial or literature evidence, and the mechanistic implausibility, this prediction should be treated as low-confidence and likely spurious rather than a genuine repurposing lead.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
New Zealand Market Information
Palivizumab currently has no market authorizations on record (market status: 未上市 / not marketed, 0 licenses).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no clinical trial or literature support (Evidence Level L5), no plausible mechanistic link between RSV neutralization and tumor pathophysiology, and shows a score-clustering pattern across 10 unrelated diseases that strongly suggests a model artifact rather than a true signal.
To proceed, the following is needed:
- TFDA/package insert safety data (currently Blocking data gap — required before any S1 safety screening)
- Formal DrugBank MOA confirmation (currently High-severity data gap)
- Independent investigation into why this drug's top predictions cluster at near-identical scores across mechanistically unrelated oncology indications, to rule out a systematic model artifact before evaluating any individual prediction in this batch
- Preclinical or mechanistic rationale specifically connecting RSV F-protein neutralization to tongue neoplasm biology, if this candidate is to be pursued further
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.